ResearcherFirst Hospital of Lanzhou UniversityActive in the last 2 years
Fangfang Han
Matched on ORCID iD 0000-0001-8019-8093; OpenAlex author ID A5003740850. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper
Papers 4
- Knockdown of PPP2R2B inhibits pancreatic cancer progression via the ERK/MAPK pathway by modulating EMT and apoptosis Co-author DOI 10.21203/rs.3.rs-5324510/v2↗
- Integrated analysis of scRNA-seq and bulk RNA-seq reveals that GPRC5A is an important prognostic gene in pancreatic cancer and is associated with B-cell Infilt… Co-author DOI 10.3389/fonc.2024.1283164↗
- Ciprofol suppresses proliferation, invasion and migration of human pancreatic cancer cells. Co-author DOI 10.36721/pjps.2024.37.2.reg.327-336.1↗
- Challenges and Opportunities Associated With Platelets in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.850485↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chunlu Dong · 3 shared papers, 2024–2025 · strength 0.70
- Paper Knockdown of PPP2R2B inhibits pancreatic cancer progression via the ERK/MAPK pathway by modulating EMT and apoptosis DOI 10.21203/rs.3.rs-5324510/v2↗
- Paper Ciprofol suppresses proliferation, invasion and migration of human pancreatic cancer cells. DOI 10.36721/pjps.2024.37.2.reg.327-336.1↗
- Paper Integrated analysis of scRNA-seq and bulk RNA-seq reveals that GPRC5A is an important prognostic gene in pancreatic can… DOI 10.3389/fonc.2024.1283164↗
- Huaqing Shi · 2 shared papers, 2024–2025 · strength 0.51
- Yan Du · 2 shared papers, 2024–2025 · strength 0.51
- Zhou Chen · 2 shared papers, 2022–2025 · strength 0.45
- Shi Dong · 2 shared papers, 2022–2024 · strength 0.43
- Wence Zhou · 2 shared papers, 2022–2024 · strength 0.38
- Wence Zhou · 1 shared paper, 2025 · strength 0.27
- Wence Zhou · 1 shared paper, 2024 · strength 0.24
- Chen Zhou · 1 shared paper, 2024 · strength 0.20
- Ru He · 1 shared paper, 2022 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.